Semaglutide Patent Expiration: Timeline, Dates, and What Comes Next

Semaglutide's core US composition-of-matter patent expires on December 5, 2031, which means brand-name exclusivity for Ozempic, Wegovy, and Rybelsus is likely to hold in the United States well into the 2030s. Protection has already ended or ends sooner in several other markets, including Canada, India, China, and Brazil. The practical answer to when does semaglutide patent expire depends on which country you are in, which patent you mean, and how much litigation follows.

Semaglutide Patent Expiration Dates Around the World

Patent rights are territorial, so semaglutide does not lose protection everywhere at once. The table below summarizes widely reported timelines for the main semaglutide molecule. Dates can shift through litigation, patent term extensions, and pediatric exclusivity awards.

Semaglutide's Canadian and Indian patents are expected to lapse in 2026, more than five years before US protection ends. That gap is why generic manufacturers in those countries are moving first.

Why the 2031 US Date Is Not the Final Word

The 2031 expiration covers the semaglutide molecule itself. Novo Nordisk also holds patents covering formulations, dosing schedules, the oral tablet used for Rybelsus, and the injection pen. Those secondary claims can keep copycat products off the market well past the headline date.

Three factors commonly push generic entry later than a single patent date suggests:

• Pediatric exclusivity: a six-month add-on granted when a manufacturer completes required pediatric studies. That alone can move US entry to mid-2032.
• Secondary patents: formulation and device claims that a generic maker must design around or challenge in court.
• Litigation and the 180-day window: the first successful generic filer receives six months of market exclusivity, and court fights can add years of delay.

US generic semaglutide is unlikely to reach pharmacy shelves before 2032, even though the molecule patent expires in 2031.

What Changes When Exclusivity Ends

Generic competition usually reshapes price and access more than it changes the medicine itself. Analysts covering GLP-1 drugs expect copycat semaglutide to cut monthly costs sharply within the first year of launch.

• Prices fall: generic injectables often enter at 50 to 80 percent below the brand price, then drift lower as more manufacturers launch.
• Formularies open up: insurers and pharmacy benefit managers typically move generics to preferred tiers with lower copays.
• Compounding shrinks: the FDA removed semaglutide from its shortage list, which ended the broad compounding allowance that let some pharmacies mix their own versions.
• Research supply shifts: laboratories that study incretin biology generally see reference-standard pricing fall once patents lapse.

Some compounded products marketed as semaglutide l carnitine paired the drug with an amino acid often promoted for fat metabolism, but compounded copies were never FDA-approved and the shortage-era window for them has largely closed.

Semaglutide vs. Tirzepatide, Retatrutide, and Cagrilintide

Semaglutide is the first GLP-1 blockbuster to face real generic pressure, but it is far from the only compound in the pipeline. Researchers comparing next-generation options often place retatrutide vs tirzepatide vs semaglutide side by side, because each one targets a different combination of receptors.

Combination research is moving quickly. Trials pairing cagrilintide and semaglutide reported strong weight-loss results in late-stage studies, and Novo Nordisk has signaled it intends to pursue approval.

Older peptides follow a completely different clock. Compounds such as AOD-9604 have been sold as research chemicals for years, so discussions of aod 9604 and semaglutide usually focus on how a growth hormone fragment compares with an incretin-based drug rather than on patent status.

Safety and Legal Notes for Consumers

A patent expiring does not make a drug over-the-counter or safe to self-dose. Semaglutide remains a prescription medicine in every approved market, and its label lists risks including nausea, vomiting, pancreatitis, gallbladder disease, and thyroid C-cell tumors observed in rodents.

Products sold as research-grade semaglutide are not FDA-approved drugs, regardless of how the label reads. Anyone considering semaglutide for weight or blood sugar management should speak with a licensed healthcare professional about approved options, dosing, and monitoring.

Cheaper generics after 2031 could widen access considerably, but they will not remove the need for medical supervision or for verified, legally sourced product.